Periodontal management of amlodipine-induced gingival hyperplasia in a hypertensive patient: A surgical approach

Background: Amlodipine is a third-generation dihydropyridine calcium channel blocker used to treat hypertension and angina. Gingival hyperplasia (GH) is an unwanted side effect associated with this therapy. It causes unsatisfactory esthetics, difficulty in maintaining good oral hygiene, abnormal too...

Full description

Bibliographic Details
Main Authors: Houda El Ayachi, Oum Keltoum Ennibi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Scientific Dental Journal
Subjects:
Online Access:http://www.scidentj.com/article.asp?issn=2580-6548;year=2021;volume=5;issue=2;spage=91;epage=96;aulast=El
Description
Summary:Background: Amlodipine is a third-generation dihydropyridine calcium channel blocker used to treat hypertension and angina. Gingival hyperplasia (GH) is an unwanted side effect associated with this therapy. It causes unsatisfactory esthetics, difficulty in maintaining good oral hygiene, abnormal tooth movement, and difficulty in mastication. GH can be managed by nonsurgical therapy alone or using a combination of nonsurgical and surgical therapy. Case Report: A 55-year-old female patient came to the clinical department of periodontology, University Hospital of Rabat, with a chief complaint of gingival enlargement. It was diagnosed and initially managed by nonsurgical periodontal treatment. Drug substitution and surgical intervention were executed. Regular supportive periodontal therapy showed a good and stable outcome over 2 years of follow-up. Conclusion: Amlodipine-induced GH can be managed using periodontal procedures combined with good oral hygiene and regular supportive periodontal therapy.
ISSN:2580-6548
2541-321X